Withdrawal of Approval of Drug Application: Kremers Urban Pharmaceuticals, Inc., Extended-Release Methylphenidate Tablets; Grant of Hearing Request
FDA is withdrawing approval of Kremers Urban Pharmaceuticals' extended-release methylphenidate tablets and granting a hearing request, which may affect the product's availability and regulatory status.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 12, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Kremers Urban Pharmaceuticals, Inc., and potentially other manufacturers of extended-release methylphenidate tablets, as well as distributors and patients relying on this product. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; follow the Federal Register notice for hearing dates and deadlines.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA is initiating withdrawal of approval for Kremers Urban's extended-release methylphenidate tablets and granting a hearing request, which could lead to the product being removed from the market.
Who it affects
Kremers Urban Pharmaceuticals, Inc., and potentially other manufacturers of extended-release methylphenidate tablets, as well as distributors and patients relying on this product.
What you must do
Monitor the hearing process and prepare for potential market withdrawal; assess supply chain impact and alternatives.
Deadline
Not specified in the excerpt; follow the Federal Register notice for hearing dates and deadlines.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness